# Panorama Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/panorama-medicine

- Industry: Healthcare IT
- Headquarters: Philadelphia, US
- Website: www.panoramamedicine.com
- Total disclosed funding: $3.7M
- Latest round: Seed (Apr 16, 2019)
- Investors on record: 3

## About

Panorama Medicine, Inc. is a biotechnology company specializing in innovative therapeutic interventions for RNA splicing defects, utilizing advanced genomics and artificial intelligence to enhance drug discovery and treatment outcomes.Founded in 2018 and headquartered in Philadelphia, US, Panorama Medicine focuses on addressing RNA splicing defects through its proprietary platforms. The company raised USD 3.7 million in a SEED funding round in April 2019, led by WI Harper Group, with participation from Delian Capital and ZhenFund. Founders Mingfu Zhu and Yi Xing are instrumental in the company’s strategic vision, while Haishan Xiong serves as CEO. The company has completed 2 deals to date.Panorama Medicine develops innovative therapeutic interventions for RNA splicing defects, leveraging proprietary platforms that combine genomics, drug screening, big data, and artificial intelligence. Their core offerings include advanced tools to selectively manipulate mRNA splicing events, addressing a wide range of genetic diseases and improving patient outcomes. Their technology is utilized by academic institutions, research organizations, and biopharmaceutical companies across North America, Europe, and Asia for drug discovery and novel therapy development.Panorama Medicine generates revenue primarily through partnerships with biotechnology and pharmaceutical companies, as well as collaborations with research institutions. The firm engages in B2B transactions, providing access to its platforms for drug discovery focused on RNA splicing. Revenue is derived from tailored agreements, milestone payments, and royalties based on collaboration success, although specific financial details are not disclosed.Following its recent SEED funding round of USD 3.7 million in April 2019, Panorama Medicine plans to expand its product offerings and enhance its technological platforms. The funding will be utilized to support the development of new products aimed at improving RNA splicing interventions. Additionally, the company is targeting expansion into new geographic markets, with plans to grow its presence in Europe and Asia by 2022, thereby increasing its international client base.

## Funding rounds

- Seed, Apr 16, 2019, $3.7M — WI Harper Group, ZhenFund, Delian Capital

## Investors

- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Seed
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Seed
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Seed